{"entity":{"id":"nct07452198","kind":"trial","name":"A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma","aka":[],"tldr":"A phase 3 trial testing GR1803 in multiple myeloma, now recruiting.","summary":"A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma is a phase 3 interventional study registered as NCT07452198, led by Genrix (Shanghai) Biopharmaceutical, and recruiting on the registry. Official title: A Phase 3, Multicenter, Open-Label, Randomised Study Comparing GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received 1 to 3 Prior Lines of Therapy Including Lenalidomide and Proteasome Inhibitors. Planned enrolment is 358 participants (estimated). The study started in 2026-03-09 and primary completion is expected in 2029-03. No results have been posted on ClinicalTrials.gov.","status":"recruiting","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT07452198","url":"https://clinicaltrials.gov/study/NCT07452198"}],"tags":["ctgov-ingest"],"related":[],"cancers":["multiple-myeloma","myeloma-relapsed-refractory"],"sections":[],"technologies":[],"targets":[],"drugs":["gr1803"],"companies":["genrix-bio"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07452198","phase":"3","setting":"A Phase 3, Multicenter, Open-Label, Randomized Study Comparing GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received 1 to 3 Prior Lines of Therapy Including Lenalidomide and Proteasome Inhibitors","sponsor":"Genrix (Shanghai) Biopharmaceutical","participation":[{"nct":"NCT07452198","source":"https://clinicaltrials.gov/study/NCT07452198","fetchedAt":"2026-10-07T16:55:45.930Z","studySha256":"e2b7f384eb5e1f9f22f1d5220be295c88251a9c84cab57244a8632ebb46f4bd7","overallStatus":"RECRUITING","lastUpdatePosted":"2026-03-25","leadSponsor":"Genrix (Shanghai) Biopharmaceutical Co., Ltd.","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":358,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["China"]}],"started":"2026-03-09","startedType":"actual","enrolled":358,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07452198/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"},{"id":"myeloma-relapsed-refractory","kind":"cancer","name":"Relapsed or refractory multiple myeloma","route":"/cancers/myeloma-relapsed-refractory/"}],"drug":[{"id":"gr1803","kind":"drug","name":"GR1803","route":"/drugs/gr1803/"}],"company":[{"id":"genrix-bio","kind":"company","name":"Genrix Bio","route":"/companies/genrix-bio/"}]}}